LifeStance reports Q3 revenue $363.8M, consensus $355.03M

“This was a record-breaking quarter for LifeStance (LFST),” said Dave Bourdon, CEO of LifeStance. “We delivered 17% organic visit growth, fueled by our strongest-ever organic productivity improvements and clinician net adds-bringing our team to approximately 8,000 clinicians. We also achieved our second quarter of positive net income this year, at $1 million, along with Adjusted EBITDA of $40 million with 11% margins, both marking new highs for us as a public company. This performance reflects improved operating leverage in G&A and positions us to raise our full-year Adjusted EBITDA guidance while continuing to expand margins into 2026. The team’s exceptional results this quarter provide strong momentum as we enter the fourth quarter and look ahead to the coming year.”